|D011024||Pneumonia, Viral NIH||0.12|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.09|
|D055371||Acute Lung Injury NIH||0.09|
There is one clinical trial.
This is an adaptive Phase IB-II trial of a vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF, to prevent COVID-19 in adults.
Description: Confirm safety of AV-COVID-19 by adverse event monitoringMeasure: Confirm safety Time: 6 months
Description: Measurement of IgG and IgM in subject bloodMeasure: Suggestion of efficacy Time: 6 months
Description: Measurement of IgG and IgM in subject bloodMeasure: Optimal dose of SARS-CoV-2 antigen Time: 6 months
Description: Measurement of IgG and IgM in subject bloodMeasure: Advantage of administering vaccine admixed with GM-CSF Time: 6 months
Description: Measurement of IgG and IgM in subject bloodMeasure: Frequency of detecting IgG against SARS-CoV-2 in blood after vaccination Time: 6 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports